NEJM: BNT162b2 vaccine is safe and effective for 12-15 year old vaccinators

As of May 21, 2021, the Covid-19 pandemic has infected more than 165 million people of all ages worldwide and caused more than 3.

Infection management prevention

Robert W.

Compared with subjects aged 16-25 years, the non-inferiority of the immune response to BNT162b2 in subjects aged 12-15 years is an immunogenic target.

immunity

Local reactions and systemic events reported within 7 days after using BNT162b2 or placebo

Local reactions and systemic events reported within 7 days after using BNT162b2 or placebo

A total of 2260 adolescents aged 12-15 were enrolled; 1131 received BNT162b2, and 1129 received placebo.

The 12-15 year-old cohort had a greater response.

Among adolescents aged 12-15, a two-dose regimen of 30 μg of BNT162b2 administered 21 days apart is safe and immunogenic, and the effectiveness of the vaccine against Covid-19 has been observed from 7 days after the second dose of vaccination Is 100%.

The BNT162b2 vaccine has good safety in 12-15 year old recipients, produces a greater immune response than young people, and is very effective against Covid-19.

RW Frenck, NP Klein, N.

RW Frenck, NP Klein, N.
Kitchin, A.
Gurtman, J.
Absalon, S.
Lockhart, JL Perez, EB Walter, S.
Senders, R.
Bailey, KA Swanson, H.
Ma, X.
Xu, K.
Koury , WV Kalina, D.
Cooper, T.
Jennings, DM Brandon, SJ Thomas, Ö.
Türeci, DB Tresnan, S.
Mather, PR Dormitzer, U.
Şahin, KU Jansen, WC Gruber, Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents, New England Journal of Medicine (2021).


Leave a message here